Supplemental Material from Ambrosioni J et al. Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection. AIDS. 2020. DOI:10.1097/QAD.0000000000002685.
Supplemental Figure 1. Flow chart of patients included from the PHI-HCB cohort.
#Boosted with either ritonavir or cobicistat
Abbreviations: PHI-HCB = Acute/recent primary HIV infection cohort of Hospital Clínic de Barcelona; ART
= Antiretroviral treatment; NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor; InSTI = Integrase strand-transfer Inhibitor.
Supplemental Figure 2. Absolute CD4 cell count (A) and CD4/CD8 ratio (B) in Acute/recent HIV-infected patients starting ART within 6 months post-infection, according to ARV regimen (NNRTI, PI or InSTI-based)
NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor; InSTI
= Integrase-Strand-transfer Inhibitor
Supplemental Table 1. Adverse events rate (overall and leading to discontinuation).
Total NNRTI PI InSTI P value
Any adverse event at 1 year [n (%)]
54 (39%) 9 (41%) 12 (43%) 33 (43%) 0.146
Discontinuation rate at 1 year [n (%)]
13 (9%) 5 (23%) § 3 (11%) 5 (6%) 0.036
Any adverse event at 3 years [n (%)]
69 (49%) 12 (55%) 14 (50%) 43 (49%) 0.145
Discontinuation rate at 3 years [n (%)]
20 (15%) 6 (27%) § 6 (21%) 8 (9%) 0.040
Abbreviations: NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor; InSTI = Integrase-Strand-transfer Inhibitor § All related to EFV side effects.
Supplemental Table 2. Adverse events (AE) at 1 and 3 years according to ARV family by intention-to- treat analysis (ITT)
Abbreviations: NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor; InSTI = Integrase-Strand-transfer Inhibitor
Adverse event Total ART regimen
NNRTI PI InSTI
1 year 3 years 1 year 3 years 1 year 3 years 1 year 3 years Gastrointestinal 14 (20%) 17 (19%) 2 (17%) 3 (19%) 4 (27%) 4 (22%) 8 (18%) 10 (19%) Pyrosis 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 0 (0%) 0 (0%) Abdominal pain 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Diarrhea 3 (4%) 3 (3%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 2 (5%) 2 (4%) Nausea 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Acute pancreatitis 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Hyperbilirubinemia 2 (3%) 2 (2%) 0 (0%) 0 (0%) 2 (13%) 2 (11%) 0 (0%) 0 (0%) Liver tests altered 1 (1%) 7 (8%) 2 (17%) 3 (19%) 0 (0%) 0 (0%) 3 (7%) 4 (8%) Gastroenteritis 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) Cutaneous 3 (4%) 4 (5%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 2 (5%) 3 (6%) Pruritus 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Rash 2 (3%) 3 (3%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 1 (2%) 2 (4%) Neuropsychiatric 20 (28%) 22 (25%) 9 (75%) 10 (63%) 3 (20%) 3 (17%) 8 (18%) 9 (17%) Dizziness 5 (7%) 5 (6%) 2 (17%) 2 (13%) 1 (7%) 1 (6%) 2 (5%) 2 (4%) Depression 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 0 (0%) 0 (0%) Headache 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 0 (0%) 0 (0%) Insomnia 9 (13%) 11 (13%) 5 (42%) 6 (38%) 0 (0%) 0 (0%) 4 (9%) 5 (9%) Vivid dreams 3 (4%) 3 (3%) 2 (17%) 2 (13%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Anxiety 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Musculoskeletal 26 (37%) 30 (34%) 1 (8%) 1 (6%) 3 (20%) 3 (17%) 22 (50%) 26 (49%) Arthralgia 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%) Osteopenia 22 (31%) 26 (30%) 1 (8%) 1 (6%) 2 (13%) 2 (11%) 19 (43%) 23 (43%) Osteoporosis 3 (4%) 3 (3%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 2 (5%) 2 (4%) Infections 2 (3%) 2 (2%) 0 (0%) 0 (0%) 1 (7%) 2 (11%) 1 (2%) 0 (0%) CMV colitis 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 0 (0%) 0 (0%) PJP 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (7%) 1 (6%) 0 (0%) 0 (0%) Impaired renal
function 6 (8%) 9 (10%) 0 (0%) 2 (13%) 2 (13%) 3 (17%) 4 (9%) 4 (8%) Lymphoma 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) Dyslipidemia 1 (2%) 2 (3%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) Fatigue 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%)
Total AE 71
(100%)
88 (100%)
12 (100%)
16 (100%)
15 (100%)
18 (100%)
44 (100%)
53 (100%) At least one AE*# 54 (39%) 69 (49%) 9 (41%) 12 (55%) 12 (43%) 14 (50%) 33 (43%) 43 (49%)